Corcept Therapeutics Incorporated is a biotechnology business based in the US. Corcept Therapeutics Incorporated shares (CORT) are listed on the NASDAQ and all prices are listed in US Dollars. Corcept Therapeutics Incorporated employs 352 staff and has a trailing 12-month revenue of around $523.5 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $34.48 |
|---|---|
| 52-week range | $20.84 - $35.22 |
| 50-day moving average | $30.64 |
| 200-day moving average | $26.60 |
| Wall St. target price | $49.70 |
| PE ratio | 32.2667 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $1.05 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $34.48 from 2024-07-24
| 1 week (2024-07-18) | 3.57% |
|---|---|
| 1 month (2024-06-25) | 13.46% |
| 3 months (2024-04-25) | 55.25% |
| 6 months (2024-01-25) | 50.17% |
| 1 year (2023-07-25) | 41.49% |
|---|---|
| 2 years (2022-07-25) | 29.77% |
| 3 years (2021-07-23) | 69.94% |
| 5 years (2019-07-25) | 212.60% |
Valuing Corcept Therapeutics Incorporated stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Corcept Therapeutics Incorporated's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Corcept Therapeutics Incorporated's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 32x. In other words, Corcept Therapeutics Incorporated shares trade at around 32x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Corcept Therapeutics Incorporated's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.61. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Corcept Therapeutics Incorporated's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Corcept Therapeutics Incorporated's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $122.8 million.
The EBITDA is a measure of a Corcept Therapeutics Incorporated's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $523.5 million |
|---|---|
| Operating margin TTM | 20.09% |
| Gross profit TTM | $396.5 million |
| Return on assets TTM | 11.97% |
| Return on equity TTM | 21.91% |
| Profit margin | 22.54% |
| Book value | $5.27 |
| Market Capitalization | $3.5 billion |
TTM: trailing 12 months
We're not expecting Corcept Therapeutics Incorporated to pay a dividend over the next 12 months.
Over the last 12 months, Corcept Therapeutics Incorporated's shares have ranged in value from as little as $20.84 up to $35.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Corcept Therapeutics Incorporated's is 0.438. This would suggest that Corcept Therapeutics Incorporated's shares are less volatile than average (for this exchange).
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California. .
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
A deep dive into the highlights and limitations of Frec.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.